Ibogaine for Depression and Anxiety

Something has changed about who takes ibogaine, and the research has not followed.

The demand moved

Ibogaine’s entire reputation was built on opioid withdrawal. Every patent, every early case series, every argument for why it might be worth the risk came from addiction.

Then look at who actually turns up. In the largest survey of the experience ever conducted, 499 people, across two treatment programmes, were asked why they had come. Three quarters came for neuropsychiatric reasons rather than for addiction.

That is one clinic and its own clientele, and two of the paper’s authors work there, so it is not a picture of the whole field. But it is the best picture anyone has, and it describes a population the evidence base was never built to answer questions about.

What exists, precisely

The trial registry lists nine ibogaine studies. Their indications are opioid use disorder, opiate withdrawal, PTSD and traumatic brain injury, alcoholism, and surveys of substance use. Depression is the registered indication of none of them. Neither is anxiety.

A 2026 scoping review of ibogaine across psychiatric disorders establishes the ceiling on the whole field: only three randomised trials exist in the entire human literature.

None is about depression. Two are about the metabolite rather than the drug. The third is about cocaine. The crossover found dose-dependent QT prolongation and a reduction in withdrawal that did not reach significance.

The review’s own conclusion is unambiguous: given ibogaine’s cardiotoxicity and narrow therapeutic margin, clinical use cannot be recommended without confirmation from larger, well-controlled trials. It adds that microdosing and escalating sequential protocols remain experimental and lack standardised definitions, which is worth knowing before reading anything about microdosing for mood.

A separate review of thirty years of research, covering 24 studies and 38 case reports, reaches the same place from the other direction: no double-blind randomised trial has demonstrated that ibogaine or noribogaine effectively treats even the indication it is best known for.

The numbers that circulate

When someone quotes an effect size for ibogaine and depression, it comes from one place.

Thirty male veterans treated at a clinic in Mexico showed a fall in depression scores from 25.6 to 3.8 at one month, an effect size of 2.80, and a fall in anxiety scores from 20.8 to 3.9, effect size 2.13. Those are among the largest figures ever reported for any psychiatric intervention.

The single most useful corrective is a second cohort. Eighty-six veterans treated at a Mexican clinic and followed for six months showed effect sizes between 0.27 and 0.41 at one month. That is a group nearly three times larger, treated comparably, reporting effects five to ten times smaller.

The question to ask before any of this

Most people reading a page about ibogaine and depression are already taking something for it. That creates a problem before efficacy is even on the table.

Ibogaine is cleared almost entirely by one liver enzyme, CYP2D6. Several antidepressants inhibit it, according to their own approved labels: fluoxetine, described as potent; paroxetine, whose inhibition is irreversible and so outlasts the last dose; bupropion, through long-lived metabolites; duloxetine; and sertraline.

In 21 healthy volunteers given paroxetine or placebo beforehand, exposure to ibogaine and its metabolite was roughly twice as high after paroxetine. The dose there was a fraction of a treatment dose and there was no cardiac endpoint, so it proves that exposure doubles and not what that does to a heart.

Separately, some psychiatric drugs lengthen the QT interval in their own right, which is the mechanism by which ibogaine kills. Citalopram’s label carries explicit warnings about dose-dependent prolongation and instructs avoidance alongside other QT-prolonging drugs.

And the clinics resolve this by requiring people to stop. The methods of the Nature Medicine study record that patients had to discontinue all psychiatric medications before arrival, along with several other drug classes. For someone whose depression is currently being held by a medication, that washout is part of the intervention and carries its own risk. Coming off antidepressants covers that washout in full, and ibogaine and bipolar disorder covers a sharper version of the same problem.

What an honest answer looks like

If the question is whether ibogaine treats depression, the answer is that the question has not been asked. Not once, not anywhere, in a design capable of answering it.

What exists is an observational signal in a self-selected group of thirty people, on unregistered instruments, at one month, with a much larger comparable cohort reporting far smaller effects. Set against that is a documented mechanism of death that produces no symptom before it happens.

Depression has treatments with randomised evidence behind them, including for people who have not responded to the first several attempts. None of them is this. Ibogaine and the heart is the page that decides whether any of the rest is worth reading.